CTOs on the Move

VHA

www.vha.com

 
VHA Inc. is a national network of not-for-profit health care organizations working together to improve performance and efficiency in clinical, financial and operational management. Since 1977, when VHA established the first hospital membership organization, the company has applied its knowledge in analytics, contracting, consulting and network development to help members and customers achieve their strategic objectives. In 2012, VHA delivered $1.9 billion in savings and additional value to members. Serving 5,100 health system members and affiliates, VHA represents more than a quarter of the nation's hospitals. VHA also serves more than 118,000 non-acute health care customers enterprise-wide. VHA is based ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.vha.com
  • 220 Las Colinas Blvd E
    Irving, TX USA 75039
  • Phone: 972.830.0000

Executives

Name Title Contact Details

Similar Companies

JJ WIld

JJ WIld is a Canton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Primewest Health System

Primewest Health System is a Alexandria, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NDRI National Disease Research Interchange

NDRI National Disease Research Interchange is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

South Florida Baptist Hospital

South Florida Baptist Hospital, Inc is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. South Florida Baptist Hospital, Inc is based in Plant City, FL. You can find more information on South Florida Baptist Hospital, Inc at www.sjbhealth.org

Elcelyx Therapeutics

lcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx`s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets.